<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="99071">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01816958</url>
  </required_header>
  <id_info>
    <org_study_id>12_1293</org_study_id>
    <nct_id>NCT01816958</nct_id>
  </id_info>
  <brief_title>Neuromodulation to Facilitate the Effect of Ketamine</brief_title>
  <acronym>TMS/ketamine</acronym>
  <official_title>Treatment of Thalamocortical Dysrhythmia Using External Neuromodulation to Facilitate the Therapeutic Effect of Ketamine.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Neuroscience Center, LLC</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The Neuroscience Center, LLC</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      application of external neuromodulation along with ketamine infusion.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      apply TMS concurrent with ketamine infusion in order to increase the likliehood &amp; strength
      of therapeutic benefit
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2011</start_date>
  <completion_date type="Actual">November 2012</completion_date>
  <primary_completion_date type="Actual">November 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Case Control, Time Perspective: Retrospective</study_design>
  <primary_outcome>
    <measure>Global Assessment of Function in DSM-4R</measure>
    <time_frame>up to 3 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>treat in order to cause remission of disability</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">35</enrollment>
  <condition>Depression</condition>
  <condition>Chronic Pain</condition>
  <condition>Substance Abuse</condition>
  <arm_group>
    <arm_group_label>chronic depression and/or pain</arm_group_label>
    <description>co-administration of TMS and infused ketamine for patients with chronic pain of psyche and/or soma</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>co-administration of TMS and infused ketamine</intervention_name>
    <description>co-administration of TMS and infused ketamine</description>
    <arm_group_label>chronic depression and/or pain</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        patients within my own clinic, suffering with chronic emotional and/or somatic pain
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  chronically ill,

          -  treatment-resistant

        Exclusion Criteria:

          -  active psychosis
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Steven R Devore Best, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Neuroscience Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Neuroscience Center</name>
      <address>
        <city>Deerfield</city>
        <state>Illinois</state>
        <zip>60015</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2013</verification_date>
  <lastchanged_date>March 20, 2013</lastchanged_date>
  <firstreceived_date>March 11, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>thalamocortical dysrhythmia</keyword>
  <keyword>transcranial magnetic stimulation (TMS)</keyword>
  <keyword>transcranial Electrical Stimulation (tES)</keyword>
  <keyword>(N-methyl-D-aspartate) NMDA-R antagonist</keyword>
  <keyword>ketamine infusion</keyword>
  <keyword>neuromodulation</keyword>
  <keyword>synergistic effect</keyword>
  <keyword>remission</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Substance-Related Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Ketamine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
